← brief for 2026-08-15 · Slowing decline

Effects of Dapagliflozin on the Bone of Patients with CKD on Dialysis.

Article B Peer reviewed Small trial

Key takeaways

Dapagliflozin did not slow kidney decline or reduce death in patients on dialysis. The study lasted 24 weeks and used a small group of patients. This drug may affect bone health, but this trial did not show changes in bone biomarkers.

Who did this work

Pelepenko LE · Barreto J · Martins MP · Chiteculo PB · Camargo JM · de Oliveira MC · Corrêa EA · Pascoa M · Guerra-Junior G · Dominguez WV · Carbonara CEM · Louvet L

Source

Article · PubMed, the drug frontier · 2026 Aug 14
https://pubmed.ncbi.nlm.nih.gov/42595915/